Breast Cancer Clinical Trials in Jinan, Shandong
14 recruitingJinan, Shandong, China
Showing 1–14 of 14 trials
Recruiting
Not Applicable
Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
Breast CancerRadiotherapy
Fudan University1,608 enrolled15 locationsNCT07469267
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 2
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Breast Cancer
Shandong Cancer Hospital and Institute72 enrolled1 locationNCT06802757
Recruiting
The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy
Breast CancerHER2/CEP17 Ratio
Shandong Cancer Hospital and Institute300 enrolled1 locationNCT07376174
Recruiting
Phase 1
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
Breast CancerOvarian CancerEndometrial Cancer
Shanghai Best-Link Bioscience, LLC9 enrolled2 locationsNCT06738966
Recruiting
Phase 1Phase 2
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Breast CancerOvarian CancerProstate Cancer+3 more
Acerand Therapeutics (Shanghai) Limited298 enrolled14 locationsNCT06380660
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 1
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled7 locationsNCT05461768
Recruiting
Phase 3
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Breast Cancer
Laekna Limited256 enrolled55 locationsNCT04851613
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 3
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.642 enrolled25 locationsNCT07003074
Recruiting
Phase 1Phase 2
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Breast CancerPancreatic CancerCancer+7 more
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.188 enrolled1 locationNCT06819215
Recruiting
Phase 1
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.150 enrolled20 locationsNCT06115902
Recruiting
Phase 3
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Breast Cancer
Genor Biopharma Co., Ltd.350 enrolled52 locationsNCT05851014